Stay updated on Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial page.

Latest updates to the Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial page
- Check5 days agoChange DetectedThe study page now notes that recruitment is closed and no longer accepting participants.SummaryDifference0.2%

- Check12 days agoChange DetectedThe recruitment status was updated to Active, not recruiting; enrollment and site counts were revised (276 estimated to 257 actual; 217 locations to 204), and the page version was bumped to v3.5.5.SummaryDifference15%

- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe study page was updated to Revision: v3.5.4, representing an internal update to the page's revision history. It does not modify any study details, endpoints, or inclusion criteria visible to users.SummaryDifference0.0%

- Check41 days agoChange DetectedThe Taiwan site listing was updated from 'Taoyuan, Taiwan, 333' to 'Taoyuan City, Taiwan, 333' to clarify the precise city designation. This clarifies the recruitment location for that site within the study's geographic footprint.SummaryDifference0.0%

- Check48 days agoChange DetectedThe page footer's Revision tag has been updated from v3.5.2 to v3.5.3, representing a new build of the page without changes to the underlying study details.SummaryDifference0.0%

- Check55 days agoChange DetectedUpdated study record dates/status entries (e.g., listing newer posted/last update timestamps and a withdrawn indicator). Removed an earlier named investigator/contact and associated role/contact/location status information.SummaryDifference0.1%

Stay in the know with updates to Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial page.